HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Competing interest statement Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hawkey, C J Search for Related Content PubMed PubMed Citation Articles by Hawkey, C J

COX-2 chronology

Correspondence to:
Correspondence to:
Professor C J Hawkey
Wolfson Digestive Diseases Centre, University of Nottingham, University Hospital, Nottingham, NG7 2UH, UK; cj.hawkey{at}nottingham.ac.uk

The role of selective cyclooxygenase (COX)-2 inhibitors in medical practice has become controversial since evidence emerged that their use is associated with an increased risk of myocardial infarction. Selective COX-2 inhibitors were seen as successor to non-selective non-steroidal anti-inflammatory drugs, in turn successors to aspirin. The importance of pain relief means that such drugs have always attracted attention. The fact that they work through inhibition of cyclooxygenase, are widespread, and have multiple effects also means that adverse effects that were unanticipated (even though predictable) have always emerged. In this paper I therefore present an historical perspective so that the lessons of the past may be applied to the present.

Abbreviations: COX, cyclooxygenase; NSAIDs, non-steroidal anti-inflammatory drugs; PPIs, proton pump inhibitors

Keywords: aspirin; non-steroidal anti-inflammatory drugs; coxibs; cyclooxygenase 2 inhibitors; salicylate; rofecoxib; celecoxib; ulcer; myocardial infarction

This article has been cited by other articles:

				R. Logan Commentary: Preventing colorectal cancer with aspirin what next? Int. J. Epidemiol., October 5, 2007; (2007) dym204v1. [Full Text] [PDF]